Xiao Xu Ming Tang (Minor Prolong Life Decoction)

Actions

Indications

Western Uses:

• What is Xiao Xu Ming Tang used for in modern practice?

  In modern practice, Xiao Xu Ming Tang (often romanized Xiaoxuming Decoction, XXMD) is referenced in Chinese clinical research as an adjunct herbal treatment alongside conventional care for ischemic stroke, at both the acute and chronic/sequelae stages. Practitioners have traditionally applied its wind-channel pattern to conditions Western medicine recognizes as stroke and post-stroke motor/speech impairment.

  This biomedical correlate is offered as a reference to the formula’s traditional use, not as a claim that it treats any disease. Because it contains Ma Huang (ephedra) and prepared Fu Zi (aconite), it requires professional preparation and supervision, and any use for a diagnosed stroke belongs with emergency medical care and a qualified practitioner — not as a substitute for either.

  Source: traditional-use correlate summarized from Bensky & Barolet, Formulas & Strategies, cross-checked against Zhang et al., Frontiers in Pharmacology 2021 (PMID 34970152 / PMC 8712731); reference only, not a treatment claim.

Originally Appeared In:

• Thousand Ducat Formulas (Qian Jin Yao Fang)

Notes:

• Is Xiao Xu Ming Tang still used today, and how does it compare to other windstroke formulas?

  Xiao Xu Ming Tang was the leading formula for windstroke through the Tang and Song dynasties, but its use narrowed after Jin-Yuan physicians (from roughly the 12th–13th centuries onward) increasingly attributed stroke to internal factors — Liver wind, phlegm-fire, and qi/blood disorder — rather than external wind invasion, favoring formulas that address internal wind instead. It remains referenced today specifically for the external-wind-invading-the-channels presentation.

  • vs formulas for internal Liver wind (e.g., Zhen Gan Xi Feng Tang-type strategies): those anchor treatment in subduing ascendant Liver yang and internal wind with heavy, cooling, anchoring herbs; Xiao Xu Ming Tang instead releases an external pathogen from a deficient body and is inappropriate where heat/yang-rising signs dominate.
  • vs Da Qin Jiao Tang: a related, later windstroke formula for the channels that omits Ma Huang and Fu Zi and leans more toward nourishing blood and clearing heat — often preferred where the aggressive warming/dispersing action of Xiao Xu Ming Tang is not desired.

  Source: Bensky & Barolet, Formulas & Strategies (historical context, comparison of windstroke formulas).

  Which "Fang Ji" does this formula use — and why the substitution?

  Modern practice substitutes Han Fang Ji (Stephania tetrandra) for the "Fang Ji" in this classical formula. Older texts used Guang Fang Ji (Aristolochia fangchi), but that species contains aristolochic acid — a potent nephrotoxin and IARC Group 1 carcinogen implicated in the 1990s outbreak of aristolochic-acid nephropathy ("Chinese-herb nephropathy") and urothelial cancer. Guang Fang Ji was removed from the Chinese Pharmacopoeia in 2005 and is restricted internationally. Han Fang Ji (Radix Stephaniae Tetrandrae), free of aristolochic acid, is the standard safe substitute and provides the wind-damp–dispelling, water-draining action the formula calls for.

  Sources: aristolochic-acid nephropathy review (PMID 28146082); IARC Group 1 classification of aristolochic acids; 2005 Chinese Pharmacopoeia removal of Guang Fang Ji.

Clinical Studies & Research:

• Is there modern research on Xiao Xu Ming Tang?

  Yes — Xiaoxuming Decoction (XXMD) has been studied in clinical and mechanistic research on ischemic stroke, though the evidence base remains limited by trial quality. A 2013 systematic review and meta-analysis of eight randomized controlled trials (601 participants, 1992–2012) comparing XXMD (usually combined with conventional treatment) to conventional treatment alone found improvements in clinical effective rate and NIHSS neurological scores in several trials, but concluded the evidence was “positive but weak” due to poor methodological quality and small trial sizes. A 2021 narrative review summarized emerging pharmacological mechanisms (vasodilation, antiplatelet/anticoagulant effects, antioxidant and anti-inflammatory activity, blood-brain-barrier protection) identified from more than 60 isolated compounds, while noting that large, high-quality RCTs and the specific active constituents responsible for clinical effects are still lacking.

  • Acute ischemic stroke (clinical, systematic review): 8 RCTs, positive but methodologically weak evidence for XXMD plus conventional care over conventional care alone (PMID 23583540).
  • Mechanisms and clinical use across stages (review): XXMD referenced as beneficial at both acute-subacute and chronic post-stroke stages in Chinese clinical studies; multiple candidate mechanisms identified but not yet confirmed clinically (PMID 34970152 / PMC 8712731).

  Sources: PubMed 23583540 (Fu et al., Journal of Ethnopharmacology, 2013); PubMed 34970152 / PMC 8712731 (Zhang et al., Frontiers in Pharmacology, 2021). Research context, not a therapeutic claim; direct high-quality clinical trial evidence remains limited.